Maravai LifeSciences Holdings Inc (MRVI) オプション

MRVI No 2 on the Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Maravai LifeSciences stock price target raised to $50 from $31 at Stifel Nicolaus
7:24 am ET March 3, 2021 (MarketWatch)

Maravai LifeSciences shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued FY21 EPS and sales guidance above estimates.

Mar 3, 2021 7:35a ETBenzinga Stock Analysis

Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The Company's segments include Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products used in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Its Biologics Safety Testing segment sells specialized analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The Company's Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry.